secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001193125-24-091875
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio completes acquisition of AnHeart Therapeutics; issues ~27.6M shares and ~85M potential convertible shares
--------------------------------------------------------------------------------

- Completed acquisition of AnHeart Therapeutics on April 9, 2024. Issued ~27.6M Class A shares, 851K Series A Convertible Preferred (convertible into ~85.1M shares), and ~2.9M warrants.
- Assumed AnHeart options and RSUs covering ~15.9M Class A shares; AnHeart shareholders own ~1/3 of combined company on fully diluted basis.
- Appointed Dr. Junyuan (Jerry) Wang (former AnHeart CEO) and Dr. Xiangmin (Min) Cui (Decheng Capital) to the board.
- Filed Certificate of Designation for Series A Non-Voting Convertible Preferred; conversion requires stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524091875/0001193125-24-091875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524091875/d824232d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-091875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer